Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy

Daniel C. Cho*, Thomas E. Hutson, Wolfram Samlowski, Peter Sportelli, Brad Somer, Paul Richards, Jeffrey A. Sosman, Igor Puzanov, M. Dror Michaelson, Keith T. Flaherty, Robert A. Figlin, Nicholas J. Vogelzang

*Corresponding author for this work

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

BACKGROUND: The clinical activity of allosteric inhibitors of mammalian target of rapamycin (mTOR) inhibitors in renal cell carcinoma (RCC) may be limited by upstream activation of phosphatidylinositol 3 (PI3)-kinase/Akt resulting from mTOR1 inhibition. On the basis of this rationale, 2 independent phase 2 trials (Perifosine 228 and 231) were conducted to assess the efficacy and safety of the novel Akt inhibitor perifosine in patients with advanced RCC who had failed on previous vascular endothelial growth factor (VEGF)-targeted therapy. METHODS: In the Perifosine 228 trial, 24 patients with advanced RCC received oral perifosine (100 mg daily). Perifosine 231 enrolled 2 groups that received daily oral perifosine (100 mg daily): Group A comprised 32 patients who had received no prior mTOR inhibitor, and Group B comprised 18 patients who had received 1 prior mTOR inhibitor. RESULTS: In the Perifosine 228 trial, 1 patient achieved a partial response (objective response rate, 4%; 95% confidence interval, 0.7%-20%), and 11 patients (46%) had stable disease as their best response. The median progression-free survival was 14.2 weeks (95% confidence interval, 7.7-21.6 weeks). In the Perifosine 231 trial, 5 patients achieved a partial response (objective response rate, 10%; 95% confidence interval, 4.5%-22.2%) and 16 patients (32%) had stable disease as their best response. The median progression-free survival was 14 weeks (95% confidence interval, 12.9, 20.7 weeks). Overall, perifosine was well tolerated, and there were very few grade 3 and 4 events. The most common toxicities included nausea, diarrhea, musculoskeletal pain, and fatigue. CONCLUSIONS: Although perifosine demonstrated activity in patients with advanced RCC after failure on VEGF-targeted therapy, its activity was not superior to currently available second-line agents. Nonetheless, perifosine may be worthy of further study in RCC in combination with other currently available therapies.

Original languageEnglish (US)
Pages (from-to)6055-6062
Number of pages8
JournalCancer
Volume118
Issue number24
DOIs
StatePublished - Dec 15 2012

Keywords

  • Akt
  • Akt inhibitor
  • mammalian target of rapamycin
  • perifosine
  • renal cancer
  • renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy'. Together they form a unique fingerprint.

  • Cite this

    Cho, D. C., Hutson, T. E., Samlowski, W., Sportelli, P., Somer, B., Richards, P., Sosman, J. A., Puzanov, I., Michaelson, M. D., Flaherty, K. T., Figlin, R. A., & Vogelzang, N. J. (2012). Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer, 118(24), 6055-6062. https://doi.org/10.1002/cncr.27668